Resveratrol improves ifosfamide-induced Fanconi syndrome in rats

Toxicology and Applied Pharmacology

Volumn 222, Issue 1, 2007, Pages 33-41

  Şehirli, Özer ^a   Şakarcan, Abdullah ^b   Velioǧlu Öǧünç, Ayliz ^a   Çetinel, Şule ^a   Gedik, Nursal ^a   Yeǧen, Berrak Ç ^c   Şener, Göksel ^a  

^a MARMARA UNIVERSITY   (Turkey)

^b UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c KASIMPASA MILITARY HOSPITAL   (Turkey)

Author keywords

Cytokine; Glutathione; Ifosfamide; Lipid peroxidation; Myeloperoxidase; Resveratrol

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIOXIDANT; COLLAGEN; CREATININE; GLUCOSE; GLUTATHIONE; IFOSFAMIDE; INTERLEUKIN 1BETA; INTERLEUKIN 6; LACTATE DEHYDROGENASE; LUCIGENIN; LUMINOL; MALONALDEHYDE; MYELOPEROXIDASE; PHOSPHATE; PROTEIN; REACTIVE OXYGEN METABOLITE; RESVERATROL; SODIUM; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR ALPHA; UREA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD SAMPLING; CHEMICAL ANALYSIS; CHEMOLUMINESCENCE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOKINE RELEASE; DECAPITATION; DISEASE SEVERITY; FANCONI RENOTUBULAR SYNDROME; GLUCOSE URINE LEVEL; HISTOLOGY; KIDNEY DISEASE; KIDNEY PARENCHYMA; NONHUMAN; OXIDATIVE STRESS; PHOSPHATE URINE LEVEL; PROTEIN URINE LEVEL; RAT; SERUM; SODIUM URINE LEVEL; UREA BLOOD LEVEL; URINALYSIS; URINARY TRACT; WISTAR FURTH RAT;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTIOXIDANTS; BLOOD UREA NITROGEN; CYTOKINES; FANCONI SYNDROME; FEMALE; GLUTATHIONE; IFOSFAMIDE; KIDNEY; L-LACTATE DEHYDROGENASE; LIPID PEROXIDATION; LUMINESCENCE; MALE; MALONDIALDEHYDE; PEROXIDASE; RATS; RATS, WISTAR; STILBENES; URINARY BLADDER;

ANIMALIA; RATTUS;

EID: 34250770438     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2007.03.025     Document Type: Article

References (65)

1. Ara C., Karabulut A.B., Kirimlioglu H., Coban S., Ugras M., Kirimliglu V., and Yilmaz S. Protective effect of resveratrol against renal oxidative stress in cholestasis. Ren. Fail. 27 (2005) 435-440
2. Badary O.A. Taurine attenuates Fanconi syndrome induced by ifosfamide without compromising its antitumor activity. Oncol. Res. 10 (1998) 355-360
3. Badary O.A. l-Histidinol attenuates Fanconi syndrome induced by ifosfamide in rats. Exp. Nephrol. 7 (1999) 323-327
4. Badary O.A. Thymoquinone attenuates ifosfamide-induced Fanconi syndrome in rats and enhances its antitumor activity in mice. J. Ethnopharmacol. 67 (1999) 135-142
5. Barnett D. Preclinical toxicology of ifosfamide. Semin. Oncol. 9 (1982) 8-13
6. Baur J.A., Pearson K.J., Price N.L., Jamieson H.A., Lerin C., Kalra A., Prabhu V.V., Allard J.S., Lopez-Lluch G., Lewis K., Pistell P.J., Poosala S., Becker K.G., Boss O., Gwinn D., Wang M., Ramaswamy S., Fishbein K.W., Spencer R.G., Lakatta E.G., Le Couteur D., Shaw R.J., Navas P., Puigserver P., Ingram D.K., de Cabo R., and Sinclair D.A. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444 (2006) 337-342
7. Berliner R.W., Kennedy T.J., and Hilton J.G. Effect of maleic acid on renal function. Proc. Soc. Exp. Biol. Med. 75 (1950) 791-798
8. Beuge J.A., and Aust S.D. Microsomal lipid peroxidation. Meth. Enzymol. 53 (1978) 302-311
9. Ellman G.L. Tissue sulfhydryl groups. Arch. Biochem. Biophys. 82 (1959) 70-77
10. Cao Z., and Li Y. Potent induction of cellular antioxidants and phase 2 enzymes by resveratrol in cardiomyocytes: protection against oxidative and electrophilic injury. Eur. J. Pharmacol. 489 (2004) 39-48
11. Chanvitayapongs S., Draczynska-Lusiak B., and Sun A.Y. Amelioration of oxidative stress by antioxidants and resveratrol in PC12 cells. NeuroReport 8 (1997) 1499-1502
12. Csiszar A., Smith K., Labinskyy N., Orosz Z., Rivera A., and Ungvari Z. Resveratrol attenuates TNF-alpha-induced activation of coronary arterial endothelial cells: role of NF-kappaB inhibition. Am. J. Physiol.: Heart Circ. Physiol. 291 (2006) H1694-H1699
13. Davies G.R., Simmonds N.J., Stevens T.R.J., Grandison A., Blake D.R., and Rampton D.S. Mucosal reactive oxygen metabolite production in duodenal ulcer disease. Gut 33 (1992) 1467-1472
14. De Kraker J. Ifosfamide in pediatric oncology. Anticancer Drugs 2 (1991) 339-341
15. Dong Z. Molecular mechanisms of the chemopreventive effect of resveratrol. Mutat. Res. 523 (2003) 145-150
16. Donnelly L.E., Newton R., Kennedy G.E., Fenwick P.S., Leung R.H., Ito K., Russell R.E., and Barnes P.J. Anti-inflammatory effects of resveratrol in lung epithelial cells: molecular mechanisms. Am. J. Physiol.: Lung Cell. Mol. Physiol. 287 (2004) L774-L783
17. Dubourg L., Philippe T., Cochat P., Baverel G., and Michoudet C. Toxicity of chloroacetaldehyde is similar in adult and pediatric kidney tubules. Pediatr. Nephrol. 17 (2002) 97-103
18. Dumas B.T., Watson W.A., and Biggs H.G. Albumin standards and the measurement of serum albumin with bromcresol green. Clin. Chim. Acta 258 (1997) 21-30
19. Fremont L. Biological effects of resveratrol. Life Sci. 66 (2000) 663-673
20. Gamst O., and Try K. Determination of serum-phosphate without deproteinization by ultraviolet spectrophotometry of the phosphomolybdic acid complex. Scand. J. Clin. Lab. Invest. 40 (1980) 483-486
21. Granados-Soto V. Pleiotropic effects of resveratrol. Drug News Perspect. 16 (2003) 299-307
22. Gusman J., Malonne H., and Atassi G. Reappraisal of the potential chemopreventive and chemotherapeutic properties of resveratrol. Carcinogenesis 22 (2001) 1111-1117
23. Hascalik S., Celik O., Turkoz Y., Hascalik M., Cigremis Y., Mizrak B., and Yologlu S. Resveratrol, a red wine constituent polyphenol, protects from ischemia-reperfusion damage of the ovaries. Gynecol. Obstet. Invest. 57 (2004) 218-223
24. Hilgard P., Herdich K., and Brade W. Ifosfamide-Current aspects and perspectives. Cancer Treat. Rev. 10 (1983) 183-192
25. Hillegas L.M., Griswold D.E., Brickson B., and Albrightson-Winslow C. Assessment of myeloperoxidase activity in whole rat kidney. J. Pharmacol. Meth. 24 (1990) 285-295
26. Kolgazi M., Sener G., Cetinel S., Gedik N., and Alican I. Resveratrol reduces renal and lung injury caused by sepsis in rats. J. Surg. Res. 134 (2006) 315-321
27. Kulpmann W.R. Reference methods for the determination of sodium, potassium, pH and blood gases with ion-selective electrodes. Eur. J. Clin. Chem. Clin. Biochem. 29 (1991) 263-267
28. Leiro J., Alvarez E., Arranz J.A., Laguna R., Uriarte E., and Prallo F. Effects of cis-resveratrol on inflammatory murine macrophages: antioxidant activity and down-regulation of inflammatory genes. J. Leukoc. Biol. 75 (2004) 1156-1165
29. Leonard S.S., Xia C., Jiang B.H., Stinefelt B., Klandorf H., Harris G.K., and Shi X. Resveratrol scavenges reactive oxygen species and effects radical-induced cellular responses. Biochem. Biophys. Res. Commun. 309 (2003) 1017-1026
30. Li Z.D., Ma Q.Y., and Wang C.A. Effect of resveratrol on pancreatic oxygen free radicals in rats with severe acute pancreatitis. World J. Gastroenterol. 12 (2006) 137-140
31. Liu R.H. Potential synergy of phytochemicals in cancer prevention: mechanism of action. J. Nutr. 134 (2004) 3479S-3485S
32. Lopez De Leon A., and Rojkind M. A simple micromethod for collagen and total protein determination in formalin-fixed paraffin-embedded sections. J. Histochem. Cytochem. 33 (1985) 737-743
33. Lott J., and Turner K. Evaluation of trinder's glucose oxidase method for measuring glucose in serum and urine. Clin. Chem. 21 (1975) 1754-1756
34. Lu M., Cai Y.J., Fang J.G., Zhou Y.L., Liu Z.L., and Wu L.M. Efficiency and structure-activity relationship of the antioxidant action of resveratrol and its analogs. Pharmazie 57 (2002) 474-478
35. Martin A.R., Villegas I., Sanchez-Hidalgo M., and de la Lastra C.A. The effects of resveratrol, a phytoalexin derived from red wines, on chronic inflammation induced in an experimentally induced colitis model. Br. J. Pharmacol. 147 (2006) 873-885
36. Martinek RG. A rapid ultraviolet spectrophotometric lactic dehydrogenase assay. Clin. Chim. Acta 40 (1972) 91-99
37. Meier T., Allenbacher A., Mueller E., Multhoff G., Wiesnet M., and Issels R. Ifosfamide induced depletion of glutathione in human peripheral blood lymphocytes and protection by mesna. Anti-Cancer Drugs 5 (1994) 403-409
38. Mimic-Oka J., and Simic T. Time course of renal glutathione levels in experimental Fanconi syndrome: an enzyme-based approach. Ren. Fail. 19 (1997) 373-381
39. Mizutani K., Ikeda K., Nishikata T., and Yamori Y. Phytoestrogens attenuate oxidative DNA damage in vascular smooth muscle cells from stroke-prone spontaneously hypertensive rats. J. Hypertens. 18 (2000) 1833-1840
40. Nissim I., and Weinberg J.M. Glycine attenuates Fanconi syndrome induced by maleate or ifosfamide in rats. Kidney Int. 49 (1996) 684-695
41. Ohara Y., Peterson T.E., and Harrison D.G. Hypercholesterolemia increases endothelial superoxide anion production. J. Clin. Invest. 91 (1993) 2546-2551
42. Saito M., Satoh S., Kojima N., Tada H., Sato M., Suzuki T., Senoo H., and Habuchi T. Effects of phenolic compound, resveratrol, on the renal function and costimulatory adhesion molecule CD86 expression in rat kidneys with ischemia/reperfusion injury. Arch. Histol. Cytol. 68 (2005) 41-49
43. Sato M., Maulik N., and Das D.K. Cardioprotection with alcohol: role of both alcohol and polyphenolic antioxidants. Ann. N. Y. Acad. Sci. 957 (2002) 122-135
44. Schoenike S.E., and Dana W.J. Ifosfamide and mesna. Clin. Pharm. 9 (1990) 179-191
45. Şener G., Sehirli O., Yegen B.C., Cetinel S., Gedik N., and Sakarcan A. Melatonin attenuates ifosfamide-induced Fanconi syndrome in rats. J. Pineal Res. 37 (2004) 17-25
46. Şener G., Tugtepe H., Yuksel M., Cetinel S., Gedik N., and Yegen B.C. Resveratrol improves ischemia/reperfusion-induced oxidative renal injury in rats. Arch. Med. Res. 37 7 (2006) 822-829 (Oct.)
47. Şener G., Toklu H.Z., Sehirli A.O., Velioglu-Ogunc A., Cetinel S., and Gedik N. Protective effects of resveratrol against acetaminophen-induced toxicity in mice. Hepatol. Res. 35 (2006) 62-68
48. Şener G., Topaloglu N., Sehirli A.O., Ercan F., and Gedik N. Resveratrol alleviates bleomycin-induced lung injury in rats. Pulm. Pharmacol. Ther. (2006) (Electronic publication ahead of print, DOI:10.1016/j.pupt.2006.07.003)
49. Shen F., Chen S.J., Dong X.J., Zhong H., Li Y.T., and Cheng G.F. Suppression of IL-8 gene transcription by resveratrol in phorbol ester treated human monocytic cells. J. Asian Nat. Prod. Res. 5 (2003) 151-157
50. Shigematsu S., Ishida S., Hara M., Takahashi N., Yoshimatsu H., Sakata T., and Korthuis R.J. Resveratrol, a red wine constituent polyphenol, prevents superoxide-dependent inflammatory responses induced by ischemia/reperfusion, platelet-activating factor, or oxidants. Free Radic. Biol. Med. 34 (2003) 810-817
51. Skinner R., Sharkey I.M., Pearson A.D.J., and Craft A.W. Ifosfamide, mesna, and nephrotoxicity in children. J. Clin. Oncol. 11 (1993) 173-190
52. Slot C. Plasma creatinine determination. A new and specific Jaffe reaction method. Scand. J. Clin. Lab. Invest. 17 (1965) 381-387
53. Sood C., and O'Brien P.J. Molecular mechanisms of chloroacetaldehyde-induced cytotoxicity in isolated rat hepatocytes. Biochem. Pharmacol. 46 (1993) 1621-1626
54. Springate J. Ifosfamide metabolite chloroacetaldehyde causes renal dysfunction in vivo. J. Appl. Toxicol. 17 (1997) 75-79
55. Springate J., Chan K., Lu H., Davies S., and Taub M. Toxicity of ifosfamide and its metabolite chloroacetaldehyde in cultured renal tubule cells. In Vitro Cell. Dev. Biol., Anim. 35 (1999) 314-317
56. Straka C., Hebart H., Adler-Reichel S., Werding N., Emmerich B., and Einsele H. Oncology 65 (2003) 94-98
57. Sullivan G.W., Sarembock I.J., and Linden J. The role of inflammation in vascular diseases. J. Leukoc. Biol. 67 (2000) 591-602
58. Sun A.Y., Ingelman-Sundberg M., Neve E., Matsumoto H., Nishitani Y., Minowa Y., Fukui Y., Bailey S.M., Patel V.B., Cunningham C.C., Zima T., Fialova L., Mikulikova L., Malbohan P., Janebova I., Nespor M., and Sun K. Ethanol and oxidative stress. Alcohol Clin. Exp. Res. 25 5 Suppl. ISBRA (2001) 237S-243S
59. Talke H., and Schubert G.E. Enzymatic urea determination in the blood and serum in the Warburg optical test. Klin. Wochenschr. 43 (1965) 174-175
60. Wagner T. Ifosfamide clinical pharmacokinetics. Clin. Pharmacokinet. 26 (1994) 439-456
61. Wallerath T., Deckert G., Ternes T., Anderson H., Li H., Witte K., and Forstermann U. Resveratrol, a polyphenolic phytoalexin present in red wine, enhances expression and activity of endothelial nitric oxide synthase. Circulation 106 (2002) 1652-1658
62. Wang J., and Chan K. Identification of new metabolites of ifosfamide in rat urine using ion cluster technique. J. Mass Spectrom. 30 (1995) 675-683
63. Wu J.M., Wang Z.R., Hsieh T.C., Bruder J.L., Zou J.G., and Huang Y.Z. Mechanism of cardioprotection by resveratrol, a phenolic antioxidant present in red wine. Int. J. Mol. Med. 8 (2001) 3-17
64. Wung B.S., Hsu M.C., Wu C.C., and Hsieh C.W. Resveratrol suppresses IL-6-induced ICAM-1 gene expression in endothelial cells: effects on the inhibition of STAT3 phosphorylation. Life Sci. 78 (2005) 389-397
65. Zalupski M., and Baker L.H. Ifosfamide. J. Natl. Cancer Inst. 80 (1988) 556-566